PMC:7299399 / 23858-24132
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T84 | 190-209 | Disease | denotes | immune dysfunctions | http://purl.obolibrary.org/obo/MONDO_0005046 |
| T85 | 237-245 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T238 | 248-251 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T239 | 252-253 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T151 | 7-16 | Chemical | denotes | adjuvants | http://purl.obolibrary.org/obo/CHEBI_60809 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T100 | 0-274 | Sentence | denotes | First, adjuvants might increase the efficacy of the vaccine, especially in subjects with impaired immunological function, such as the elderly, or in subjects with comorbidities resulting in immune dysfunctions; in these patient cohorts, SARS-CoV-2 has a high lethality rate. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 349 | 220-227 | Species | denotes | patient | Tax:9606 |
| 350 | 237-247 | Species | denotes | SARS-CoV-2 | Tax:2697049 |